Most studies test for mutations in the kinase domain of the abl gene in chronic myeloid leukemia (CML) using peripheral blood (PB) cells. Frequently, progression of the disease manifests with increased blasts in bone marrow (BM) and not in PB. Simultaneous analysis of plasma, PB cells and BM cells from 41 imatinib-resistent CML patients showed mutations in 63% of PB cells and 68% of plasma or BM cells (P ¼ 0.04). In discordant patients, 13 mutations were detected in plasma, 11 in BM cells and 9 in PB cells. The T315I mutation was detected in plasma and BM but not PB cells in one patient. We detected no mutations in the plasma of 45 previously untreated CML patients, but two of these patients showed mutations in plasma and not cells by 9 months on therapy. Circulating plasma mRNA is a reliable alternative to BM mRNA for detecting ABL mutations.
Introduction
Chronic myelogenous leukemia (CML) is caused by chromosomal translocations resulting in a fusion protein, BCR-ABL, with constitutive tyrosine kinase activity. Monotherapy with imatinib, a specific inhibitor of BCR-ABL tyrosine kinase activity, is effective for all stages of CML. [1] [2] [3] However, a minority of chronic-phase CML patients and many with advanced disease are initially refractory to imatinib, or develop resistance to it during treatment. 4, 5 The most common resistance mechanism is the appearance and clonal selection for point mutations in the ABL kinase domain that partially reduce or completely abrogate the binding affinity of imatinib for its target. [4] [5] [6] [7] It is important to identify what mutations, if any, are present in the BCR-ABL kinase domain of imatinib-resistant patients because the choice of subsequent therapy may depend upon the properties of the mutations present. For example, resistance caused by some mutations that only partially compromise drug binding may be overcome by escalation of the imatinib dose, whereas resistance caused by mutations that completely preclude drug binding, such as T315I, cannot be and will require alternative therapy. 5, 8, 9 Mutations in the ABL kinase domain are identified by sequencing reverse transcriptasepolymerase chain reaction (RT-PCR) products amplified from BCR-ABL mRNA, which is usually prepared from peripheral blood (PB). This approach assumes that the leukemic cells in PB contain ABL domain mutations that are representative of the total population. However, disease progression in CML patients frequently manifests with increased blasts in bone marrow (BM) rather than in PB. Our previous work has shown that plasma prepared from PB contains tumor-specific DNA, RNA and proteins.
10-13 Therefore, we analyzed whether BCR-ABL kinasedomain mutations detected in plasma correlated with mutations detected in PB and BM cell samples from imatinib-resistant CML patients. Plasma samples from imatinib-sensitive CML patients were also analyzed to assess the reliability of plasma for the detection of mutations during the course of treatment.
Methods
Parallel BM, PB and plasma samples were obtained from imatinib-resistant CML patients according to IRB-approved protocol. Resistance was defined as failure to achieve or loss of a complete hematologic response after 3 months of therapy or failure or loss of at least a minimal cytogenetic response after 6 months of therapy. Samples were prepared for RT-PCR as described. 7 An 863 bp RT-PCR product encompassing the kinase domain of BCR-ABL was amplified using a forward primer that annealed in BCR exon b2 and a reverse primer that annealed at the junction of ABL exons 9 and 10. 7 The products were sequenced in forward and reverse directions using dye terminator chemistry and an ABI sequencer (Applied Biosystems, Foster City, CA, USA).
Results and discussion
Parallel samples from BM cells, PB cells and plasma from 41 imatinib-resistent CML patients were tested for the presence of mutations in the ABL kinase domain. Mutations in the ABL kinase domain of BCR-ABL were determined by bi-directional sequencing of RT-PCR products. For 33 of 41 (80%) patients, sequencing results were consistent among the three types of samples (Table 1) . Only 63% of cases had mutation when PB cells were used, whereas 68% of samples had mutations when plasma or BM cells were used (P ¼ 0.04). Thirteen of 41 (32%) patients had a wild-type BCR-ABL kinase domain with no amino-acid changes, using the three sample types. Thirteen different amino-acid changes were detected in all three sample types from 20 patients ( Table 1) . Two of these patients had more than one mutation. Mixed populations of wild-type and mutant kinase domains were detected in all three sample types in six of these 13 cases (46%) ( Table 1) .
In eight of 41 (20%) imatinib-resistant patients, discordance in detecting ABL kinase mutations was noted between BM cells, plasma and PB cells (Table 1) . Among the eight patients with discordant results, 13 different mutations were detected in plasma, 11 in BM cells and 9 in PB cells. Representative sequences from patients with discordance are shown in Figure 1 . Interestingly, in all cases, the detection of the mutant peak is more obvious in the plasma samples than in the cells samples. The plasma RNA appeared more enriched by the mutant BCR-ABL mRNA (Figure 1 ). We speculate that the cells that carry the mutation have higher proliferation and apoptosis and turnover, which leads to higher relative ratio of mutant mRNA. In one patient, the highly resistant T315I mutation was also detected in plasma and BM, but not in PB cells (Table 1) . A silent mutation, a nucleotide substitution that did not result in an amino-acid change, was detected in plasma, but not in BM or PB from one patient (Table 1) .
PB, BM and plasma samples from 45 imatinib-sensitive CML patients were analyzed. None showed a mutation in the BCR-ABL kinase domain before imatinib treatment. However, in follow-up samples from PB cells and plasma during treatment with imatinib, two of these patients showed the appearance of mutations in plasma, but not in PB cells. One had F311L mutation at 6 months on therapy and the second patient had a silent mutation at G303 at 3 months. Both mutations disappeared at subsequent sampling. One additional patient from this group showed transient F486L mutations at 9 months on therapy in both plasma and PB cell samples. This mutation disappeared by 12 months. A fourth patient showed the E255V mutation in both plasma and PB cells at 6 months with evidence of resistance.
This study not only shows that PB cells are the best source for testing for ABL kinase mutations, but also confirms the value of plasma as a source of RNA for monitoring patients with CML. Our study shows that when plasma is used, the chance of detecting mutation in the ABL kinase domain is better than when PB and BM cells are used. This is consistent with previous results showing that DNA, RNA and proteins from leukemic cells are found in plasma and plasma is enriched by RNA from aggressive subclone. 12, 13 Our data show that free RNA from K562 cells is immediately degraded when added to normal plasma, but when K562 cell lysate is added, the BCR-ABL RNA Table 1 Results of BCR-ABL mutation in BM cells, PB cells and plasma samples from imatinib-resistant CML patients
No. of patients BM Plasma PB 13  None  None  None  2  M244V  M244V  M244V  3  G250E  G250E  G250E  1  G250E, F359I  G250E, F359I  G250E, F359I  1  G250E, F359V  G250E, F359V  G250E, F359V  1  Y253F  Y253F  Y253F  1  F311I  F311I  F311I  1  F311L  F311L  F311L  2  T315I  T315I  T315I  1  F317L  F317L In panel c, the three sample types show the detection of 944C4T (T315I) mutation, but the plasma shows that almost all the analyzed RNA is of the mutant clone, whereas the PB and BM cells show significant RNA generated from the unmutated clone.
Concordant results
Plasma and Abl kinase mutations W Ma et al can easily be detected (data not shown). This suggests that the RNA detected in the plasma of these patients is most likely not free and perhaps complexed with other proteins. This RNA is most likely resulting from the turnover of cells in various tissues. The data presented here also support the concept that imatinib-resistant patients have multiple clones of leukemic cells, some containing the wild-type BCR-ABL kinase domain and some a mutated BCR-ABL. This not only indicates that sensitive means must be used to detect subclones, but also suggests that factors other than mutations may play a significant role in the imatinib resistance.
In summary, plasma is a reliable source for mRNA for the detection of BCR-ABL mutations and can be used as an alternative to BM, but PB cells may not be adequate to rule out the presence of mutations in the BCR-ABL kinase domain.
